Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would expect Fluticare to be in stores soon and would not be surprised if CVS and Innovus are working on stocking hundreds of stores with Fluticare and some other products. I believe Dr Damaj is working on some really big ventures and they have some great products that will be coming out soon. In addition some of the partners that sale Innovus products have some products that Innovus may put out on the market later in the US.
Not sure what the sales are right now. I think it probably just hit stores in August and they won't have sale results until the end of the month but here are the store locations.
Retail Locations
Pharmacy Store #9
339 SQUIRE ROAD
Revere, MA 02151 CVS Pharmacy Store #632
4 BROADWAY ROAD
Brighton, MA 01826 CVS Pharmacy Store #3890
207 Market St
Brighton, MA 02135
CVS Pharmacy Store # 995,
2 MILLISTON RD
Millis, MA 02054 CVS Pharmacy Store #2171
63 Canal Street
Millbury, MA 01527 CVS Pharmacy Store #6466
2340 GAR HIGHWAY
Swansea, MA 02777
CVS Pharmacy Store #360
585 RIDGE RD.
North Arlington, NJ 07031 CVS Pharmacy Store #1292
1330 BALLTOWN ROAD
Niskayuna, NY 12309 CVS Pharmacy Store #5104
496 COUNTY ROAD 111, BUILDING C,
Manorville, NY 11949
CVS Pharmacy Store #5368
1220 PENINSULA BLVD,
Hewlett, NY 11557 CVS Pharmacy Store #2065
11 MAIN ST.,
Wakefield, RI 02879 CVS Pharmacy Store #5107
41285 S. COUNTY TRAIL
East Greenwich, RI 02818
Innovus has listed the CVS retail locations they are selling products out of on there website. Only a matter of time before the majority of products are selling from CVS.
With the potential purchase of Aetna by CVS this relationship with CVS and Innovus products could be huge!!!
Market watch and its on Innovus site under news. Can't wait to join u in Fiji
Market Watch
They are on a roll!!! With more potential products to follow
Innovus Pharma Signs Purchase Agreement with CVS
More Great News!!!
Innovus Pharma Signs Purchase Agreement with CVS Pharmacy, Inc. to Sell Its Product Androferti® to Increase Sperm Quality in Their Newly Established In-Store Men’s Clinic
CVS Men’s Health Clinic Pilot Program to Promote Androferti® in 12 to 20 Stores with the Potential, if Successful, to Expand Nationwide and Add Additional Products
July 19, 2018 06:05 AM Eastern Daylight Time
SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that it has entered into a pilot program with the nationwide pharmaceutical chain CVS Pharmacy, Inc. (“CVS”), which is a subsidiary of CVS Health Corp (NYSE: CVS), to sell the Company’s product Androferti®, to increase sperm quality. If successful, the CVS pilot program could lead to the national pharmacy stocking and selling Androferti® on a scalable level nationwide and could expand to add additional Innovus Pharma products.
“In addition, we are in discussion to potentially add more product under this program.”
Tweet this
“We are very pleased to have been chosen by CVS to be part of their newly established in-store men’s health clinic,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “In addition, we are in discussion to potentially add more product under this program.”
About Androferti
Androferti®, is a patented dietary supplement shown in multiple published clinical trials to statistically increase seminal quality (concentration, motility, morphology and vitality) and enhance spermatozoa quality (decreases of vacuoles in the sperm nucleus, decreases DNA fragmentation, decreases the dynamics of sperm DNA fragmentation, and improvement on the inventory of mobile sperm (“REM”)).
The Company believes that Androferti® is the only product clinically proven in multiple published clinical trials to increase the Sperm Quality and enhance Spermatozoa Quality as compared to other products where the claims are based primarily on an ingredient used in the products.
According to reports by IBIS World in August 2014, the fertility market is estimated to be around $2 billion with a 2.5% annual increase. There are currently 682 In-Vitro Fertility (IVF) clinics in the U.S. Androferti® is currently available directly to IVF clinics and online at www.myandroferti.com at a price of $95 per box, which is sufficient for a one month supply. For optimal results from the published clinical trials optimal results of Androferti® are observed with 3 months of continuous use.
About Innovus Pharmaceuticals, Inc.
Innovus has a new product on Amazon. This stock will rise, you just have to be patient. Damaj really started pushing the products in 2015. Anyone that runs a business know you have to give it 5 years. He is right on pace and several companies with no profits stock is higher. This stock would be higher if it was not shorted. If this was not a good company WestWard would not touch them nor would Amazon, Walmart etc be associated with them. Dr Damaj is building Fluticare so that it sales long term consistently over time to Drs because repeat money is the best money. He is saving dollars and waiting for the right time. I would not sale my stock because Damaj has some tricks up his sleeve and this company can explode any day if he release a surprise deal with another large pharma or partner.
Yadmon, before I invest my philosophy is to get as much information and do all the dd possible. To not look at all the variables is to get married without knowing who the person really is. Once I have done my homework and believe in it I Invest hoping for the best but knowing if it does not work it was not from DD it just did not work. People that flip that's like meeting someone and not knowing much about them but getting married and hoping for the best. It may work but who wants to deal with that pressure and stress. I like slow and steady which I think Innovus is. So Im invested and waiting for this long term. Thanks!
This was a question I asked on the first confrence call. It was addressed about the RS. Dr Damaj answer was " we don't want to do a RS . I mean I have the most shares here so I am looking for the best value for the shareholders". This was discussed and that is why Im answering this question.
Rnoutlaw26 This is true. No one really wants a RS even management said they don't want to in the confrence call. We are all hoping to get there on value but even a one time rise when fluticare is approved can reach the $3 mark for the day.
Hi John Kent, not a flipper at all but you have to always look at all the scenarios. No one has a crystal ball so you never know what a company will do or how the market will change. I am hoping no stock split but hopes or just not reality. I bought additional share just in case the do a RS but Im preparing for the worse and hoping for the best.
Stock investor 56 I agree
10/1 is not really good because you lose to many shares. 3/1 or at most 7/1 allow you to keep some shares and you can sale shares periodically without running low on shares. A R/S is good for uplisting and the probability of the stock rising increases but no one really wants to go from 100,000 shares to 10000 because it eliminates your flexibility.
A R/S still may not happen. It is a 4 month process to uplist and last time I checked they were only preparing the paperwork. I think they will wait until Fluticare approval and see how far the stock will bounce and then figure out if they still need to do a R/S. it only has to be at $3 for one day to uplist.
Bayer’s ClariSpray™ Success Bodes Well for Innovus Pharmaceuticals’ FlutiCare™
By Ryan Allway · Wednesday, August 24th, 2016
Bayer AG expanded its allergy portfolio in the United States to include ClariSpray™, a 24-hour nasal spray to treat allergy symptoms, in April 2016. Though the two drugs contain different ingredients, the company was looking to play off of the already successful Claritin™ brand. Despite a weak allergy season in the United States, the company’s Claritin™ division ‘developed positively’ during the second quarter ‘due primarily’ to the launch of the nasal spray, with revenue expanding by a currency-adjusted 11% to $178 million euros.
To syndicate this article, or for more information, please contact us online or call (406) 862-5400.
In this article, we will take a look at how this success could bode well for Innovus Pharmaceuticals Inc. (OTC: INNV) and its FlutiCare™ product under review by the FDA.
Blockbuster Drug
ClariSpray™ is an over-the-counter nasal spray that contains fluticasone propionate, which is the generic name of Glaxosmithkline plc’s Flonase. The new product was strongly promoted with television ads across most major networks in an effort to compete with the $45.4 million spent by Flonase and $26.3 million spent by Sanofi’s Nasacort on advertising since their respective launches in the nasal spray market.
ClariSpray’s™ success in the market shouldn’t come as a surprise to those following the nasal spray market. According to some sources, Glaxosmithkline’s Flonase peaked at around $1.3 billion in sales, which places it clearly in the ‘blockbuster’ category of drugs. The company has only a handful of competitors in the market at the moment, which has created a great opportunity for Bayer to take advantage of the gap.
The same opportunity drew Innovus Pharma to pursue its own version of the generic drug, particularly given the expansive distribution network that it has built over the years for its wellness product lines and the limited ANDAs approved in the US by the FDA for the active fluticasone propionate.
Brand Wars
While Bayer’s ClariSpray™ leverages the powerful Claritin™ brand name, Innovus Pharma hopes to capitalize on the leading prescription nasal allergy medication’s reputation in the market. The company secured the rights to market FlutiCare™ – the #1 prescription form in the nasal allergy space with over 177 million units sold – as an over-the-counter drug. The ‘prescription strength’ brand could benefit from its history as a doctor-recommended medication.
Currently, FlutiCare™’s fluticasone propionate is awaiting an ANDA decision from the FDA that’s expected over the coming month or two. With the drug’s robust safety and efficacy profile, the company doesn’t expect to meet any resistance from the FDA when making the decision. Management has also already signed a manufacturing agreement for the supply of FlutiCare™ 60 and 120 spray bottles and plans to leverage its existing distribution network that reaches over 30,000 stores in the U.S.
Innovus trades with a market capitalization of just over $40 million, according to Google Finance. Capturing just a fraction of the billion-dollar market could translate to a significant opportunity for the company given its small size.
Looking Ahead
Bayer’s success with ClariSpray™, Glaxosmithkline’s success with Flonase™, and Sanofi’s success with Nasacort™ all bode well for Innovus’ potential upcoming launch of FlutiCare™. Rather than relying on a strong consumer brand, the company purchased the rights to the leading prescription form in the space, which could be a compelling differentiator from the competition. The company’s modest market cap also creates significant room for upside for investors.
Daytona52. The products are not exactly the same but they do have the same main ingrident in this case being fluticasone. So everyone will have the ingrident fluticasone but just like other generics they will be a little different and that difference is what allow some products to work better for some people along with the delivery of the product. Flonase does not work for me but Hi Tech fluticasone does work for me even though they both have fluticasone. Hi tech Fluticasone Rx is the generic of Flonase but now it will be the OTC generic of Hi Tech fluticasone. The names of the generics is not really a big deal as you can see from the article below.
l.Drugs often have several names. When a drug is first discovered, it is given a chemical name, which describes the atomic or molecular structure of the drug. The chemical name is thus usually too complex and cumbersome for general use. Next, a shorthand version of the chemical name or a code name (such as RU 486) is developed for easy reference among researchers.
When a drug is approved by the Food and Drug Administration (FDA—the government agency responsible for ensuring that drugs marketed in the United States are safe and effective), it is given a
Generic (official) name
Brand (proprietary or trademark or trade) name
For example, phenytoin is the generic name and Dilantin is a brand name for the same drug.
The generic name is assigned, in the United States, by an official body—the United States Adopted Names (USAN) Council.
The brand name is developed by the company requesting approval for the drug and identifies it as the exclusive property of that company.
When a drug is under patent protection, the company markets it under its brand name. When the drug is off-patent (no longer protected by patent), the company may market its product under either the generic name or brand name. Other companies that file for approval to market the off-patent drug must use the same generic name but can create their own brand name. As a result, the same generic drug may be sold under either the generic name or one of many brand names
Generic and brand names must be unique to prevent one drug from being mistaken for another when drugs are prescribed and prescriptions are dispensed. To prevent this possible confusion, the FDA must agree to every proposed brand name.
Government officials, doctors, researchers, and others who write about the new compound use the drug’s generic name because it refers to the drug itself, not to a particular company’s brand of the drug or a specific product. However, doctors often use the brand name on prescriptions, because it is easier to remember and doctors usually learn about new drugs by the brand name.
Generic names are usually more complicated and harder to remember than brand names. Many generic names are a shorthand version of the drug’s chemical name, structure, or formula. In contrast, brand names are usually catchy, often related to the drug’s intended use, and relatively easy to remember, so that doctors will prescribe the drug and consumers will look for it by name. Brand names often suggest a characteristic of the drug. For example, Lopressor lowers blood pressure, Vivactil is an antidepressant that might make a person more vivacious, Glucotrol controls high blood sugar (glucose) levels, and Skelaxin relaxes skeletal muscles. Sometimes, the brand name is simply a shortened version of the drug’s generic name—for example, Minocin for minocycline.
The term generic, when applied to such items as foods and household products, is used to describe a less expensive, sometimes less effective or lower-quality copycat version of a brand-name product. However, most generic drugs, although less expensive than the comparable brand-name drug, are as effective and of the same quality as the brand-name drug (see Bioequivalence and Interchangeability of Generic Drugs). In fact, generic drug makers manufacture many brand-name products for companies that control the brand names. Sometimes, more than one generic version of a drug is available. For example, many manufacturers sell versions of acetaminophen.
Daytona24 , They are not releasing who the manufacturer is because they do not want other companies to know who they may be using. My guess is they will be using Cardinal because they already have a relationship with them and that is who was manf the Rx fluticasone for Hi-Tech. Since Fluticare is basically the OTC of Hi Techs fluticasone they are familiar with the product and process. Could be wrong but it would make since to use Cardnial.
Shawn P, Very true It is good to converse so that we can learn something from the boards everyday and get some questions answered. We are all here to make some money and gain some new knowledge.
Thx Honeycomb 777 and I agree with you the connections and exp of Dr D can get it done and this was the best partnership to expand quickly and best stock value for all of them.
Shawn P 123 You are correct but focus on Novalere not Innovus. They had being time Pharma people on there team and Dr. Clayton is a consumer healthcare and pharmaceutical industry veteran. Prior to joining Novalere, Dr. Clayton was Senior Vice President of Scientific and Regulatory Affairs for Schering-Plough HealthCare Products, a position he held for more than 20 years. During his career, Dr. Clayton responsibilities included clinical research, regulatory affairs, product development, product safety, and quality assurance. He was responsible for the development and launch of numerous new consumer healthcare products under such brands as Claritin, Afrin, Drixoral, Coricidin, ChlorTrimeton, Coppertone, Correctol, Dr. Scholl, Solarcaine, Lotrimin, Tinactin, and A + D. Dr. Clayton had significant involvement in the successful switch of more than 10 prescription drugs to non- prescription status, including Claritin, Drixoral, Chlor-Trimeton, Gyne-Lotrimin, Lotrimin, and Afrin. Research programs under his direction also led to advancements in ultraviolet protection through broader-spectrum, higher SPF sunscreens.
Prior to joining Schering- Plough, Dr. Clayton was employed by the U.S. Food and Drug Administration. He has held several leadership positions in the Consumer Healthcare Products Association, including serving as Chairman of both its Scientific Affairs and FDA Relations Committees, and was the industry’s primary liaison with FDA for development of standardizing Drug Facts Labeling for OTC medicines.
Innovus Pharma Announces the Approval of the Product Licenses for Zestra, Zestra Glide, EjectDelay and Sensum+ by the Indian FDA (Directorate General of Health Services) through its Partner Khandelwal Laboratories
Posted: Aug 19, 2016 3:05 AM PDT
SAN DIEGO --(BUSINESS WIRE)
Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage cash flow positive pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced today that its partner Khandelwal Laboratories received the approval of the product licenses for Zestra®, Zestra Glide®, EjectDelay® and Sensum+® from the Indian FDA, The Drugs Controller General (India), and the Directorate General of Health Services to commercialize the products in India.
"We are thrilled to have received the approval to commercialize our products from the Indian FDA in a very short time due to the strength of the dossier and the clinical trials. India is our seventh country where we have our products approved and we look forward to start the commercial launch by our partner Khandelwal Labs in the very near future," said Dr. Bassam Damaj, President and CEO of Innovus Pharmaceuticals, Inc.
On September 10, 2015 Innovus Pharma entered into an exclusive marketing and distribution agreement with Khandelwal Laboratories based in India ("KLab") under which Innovus Pharma has granted to KLab an exclusive ten-year license and distribution rights to market and sell Innovus Pharma's products. These products include Zestra® to increase Female Sexual Arousal and Desire and Satisfaction, EjectDelay® for treating premature ejaculation, Sensum+® to increase penile sensitivity and Zestra Glide®, the high-viscosity water-based lubricant. If KLabs exceeds its minimum yearly orders, the agreement has two five-year term extensions. Under the agreement, the minimum orders for the first term of the agreement are over two million and six hundred thousand ($2.6M) US dollars annually.
About Zestra® and Female Sexual Interest/Arousal Disorder (FSI/AD)
Zestra® is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women. Zestra® is the first Natural Health Product (NHP) to receive approval for the indication of FSI/AD in Canada as an NHP. To date, the Company believes that no product has been approved to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress. Published papers on the FSI/AD market size estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger. Zestra® is currently available in the United States, Canada and Morocco. For more information visit www.zestra.com.
Fluticare is the generic name that will be sold in the US. Just like other generics you can not use the same name as the Rx. Fluticasone in the US is sold from Hi Tech which is prescribed RX only and the picture in the presentation from Innovus. I have used this perscription plenty of times and have the box that matches the picture and it works great. I assume that the fluticasones are recieved from India where it is refered to as Fluticare. In one of the video interviews dated April 2 2015 Dr Damaj says that this rights is from HiTech/Acorn. Also Hi-tech/ Acorn talks about the generic being filed in one of there previous Confrence calls. It's just a matter of time. This is the real deal. This Fluticasone has been a best seller in the US and will do great otc as the numbers Innovus are using are very modest because they will reach $30 mil very quickly in the US.
I don't think the 96 mil shares is a bad things since they are mainly insider owned and to a selective few investors who seem to be waiting for bigger $. I think the shares owned allow them to have more control over the stock price and not the short investors.
Future outlook, Long term for Innovus
DUBLIN --(BUSINESS WIRE)
Research and Markets has announced the addition of the "Global Premature Ejaculation Treatment Market 2016-2020" report to their offering.
The global premature ejaculation treatment market is forecast to grow at a CAGR of 9.65% during the period 2016-2020.
The report covers the present scenario and the growth prospects of the global premature ejaculation treatment market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of premature ejaculation drugs and premature ejaculation solutions.
Technavio's report Global Premature Ejaculation Treatment Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years.
Questions Answered:
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What are the challenges to market growth?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Companies Mentioned:
Absorption Pharmaceuticals
Allergan
Innovus Pharmaceuticals
Plethora
Aytu BioScience
Bayer
Dong-A Pharmaceutical
Eli Lilly
Emcure
Futura Medical
GlaxoSmithKline
NeuroHealing Pharmaceuticals
Pfizer
Report Structure:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Market landscape
PART 06: Geographical segmentation
PART 07: Market segmentation by route of administration
PART 08: Market segmentation by mechanism of action
PART 09: Market segmentation by off-label drugs
PART 10: Market drivers
PART 11: Impact of drivers
PART 12: Market challenges
PART 13: Impact of drivers and challenges
PART 14: Market trends
PART 15: Vendor landscape
PART 16: Key vendor analysis
PART 17: Appendix
PART 18: About the Author
For more information about this report visit http://www.researchandmarkets.com/research/kwmxld/global_premature
View source version on businesswire.com: http://www.businesswire.com/news/home/20160817005372/en/
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Copyright Business Wire 2016
This article was originally distributed via Business Wire. Business Wire, Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com
Including new product launches Timeline.
8k filed Today from Innovus. Updated Presentation
Patience, Everything takes time. For those who want to sell because they feel like the profit they made makes them happy I say Congrats and enjoy. For those who are holding long and approval comes it will have been worth the risk and we will be happy at that point. I don't think Innovus is worried at all. Has anyone looked at the team Novalere had to put this fluticare submittal in to the FDA?. This team was made up of former Adams Respirtatory members who played a huge part in getting Mucinex and other products OTC approved. This was not there first rodeo. They also had a former FDA employee on there team
"Dr. Clayton is a consumer healthcare and pharmaceutical industry veteran. Prior to joining Novalere, Dr. Clayton was Senior Vice President of Scientific and Regulatory Affairs for Schering-Plough HealthCare Products, a position he held for more than 20 years. During his career, Dr. Clayton responsibilities included clinical research, regulatory affairs, product development, product safety
I am sure he helped prepare labels and submittals with his exp. This is why I think Innovus is confident they will get approval. Dr. Damaj works perfectly with Novalere plan when it comes to expansion because he already has connections around the world to distribute Fluticare and they were able to acquire more shares than they would selling to a larger company with the potential of those share rising quickly after approval.
Patience.
Yes, Fluticare Approval with Q2 fin which I think will be close to $1m could take this stock really high. I think people are going to be surprised with Innv revunues. I will not be surprised if Innv purchase another high grossing product soon also.
Agree, I think just between a few of us on this board we hold 6-7 million shares for the long haul and don't plan on departing anytime soon. Lots of floating shares but small amount of people holding those shares. Some of the vendors they deal with (Cardinal) are Fortune 500 companies that can get fluticare out quickly.
Honeycomb your observations look spot on, I agree the OS may seem higher but IMO in addition to raising Capitol for fluticare this allows Innovus to issue a large amount of shares to who they prefer to have control of a large number of shares to help control the fluctuation of the stock price later on. The investors will be holding on for the long haul.
Will do!!
The 1 neg is the approval time was moved q3/4. Pos $3-5mil and fluticare is still looking like it will be approved